CVS Health Corp vs T-Mobile Us Inc — how do they compare? CVS Health Corp trades at $93.63 (market cap $119.58B), while T-Mobile Us Inc trades at $177.23 (market cap $191.56B). The key difference: T-Mobile Us Inc is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| CVS | TMUS | |
|---|---|---|
Market Cap | $119.58B | $191.56B |
Sector | Health | Media |
52-Week High | $110.60 | $259.01 |
52-Week Low | $65.51 | $167.65 |
Enterprise Value | $181.93B | $308.17B |
Dividend Yield | 2.84% | 2.28% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.
The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.
T-Mobile US (TMUS) trades at $178.16, up 0.55% with neutral technical signals. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent Q2 2026 earnings beat expectations with $2.99 EPS versus $2.59 estimate. The company completed a $2.9B spectrum sale to Grain Management in August 2026, enhancing cash position. Analyst consensus remains strongly bullish with 44 buy ratings and $233.20 price target, representing 31% upside potential.
TMUS presents compelling growth prospects with expanding broadband momentum and consistent earnings beats, though faces competitive pressure from SpaceX's Starlink mobile ambitions. The stock trades at reasonable valuations (P/E 18.68, EV/EBITDA 9.55) with strong institutional support. Key risks include wireless market saturation and technological disruption from new entrants. Current levels offer attractive entry point for long-term investors given the significant analyst upside and dividend growth potential.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →